Kailera Therapeutics began trading on the Nasdaq on Thursday under the ticker KLRA, pulling off a $625 million IPO that the company and its backers are calling the largest biotech listing in years. The real headline may not be the check size, though. It is what Kailera is cashing in on.
The company's lead drug, ribupatide, posted Phase 2 results last year showing participants lost a mean of 23.6 percent of their body weight in just 12 weeks at the highest dose (SEC S-1 Filing). For context: Eli Lilly's tirzepatide — the active ingredient in Zepbound and Mounjaro — took 72 weeks in its pivotal trial to produce a mean weight reduction of 20.9 percent (NEJM). Different trial designs, different timelines, no head-to-head study. But the numbers are close enough to demand attention.
Ribupatide is a weekly injectable GLP-1 and GIP receptor dual agonist, the same receptor architecture as tirzepatide, licensed from Chinese pharmaceutical company Jiangsu Hengrui Pharmaceuticals. Kailera launched in May 2024 with a $400 million Series A, raised a $600 million Series B in October 2025, and is now public less than 24 months after founding (AllSci). Hengrui retains a 13.6 percent stake (AllSci). Bain Capital Private Equity, Bain Capital Life Sciences, and Qatar Investment Authority are all in for $225 million of the IPO through insider purchases (AllSci) — a signal of confidence that does not come cheap.
The $625 million raised is the most by any US biotech since 2021, according to Bloomberg (Bloomberg), which cited IPO data. Kailera priced at $16 per share, the top of its $14-to-$16 range, on 39.1 million shares (GlobeNewswire).
Phase 3 trials for injectable ribupatide are underway, with the company allocating roughly $625 million of IPO proceeds toward development through the second quarter of 2028 (BioSpace). The Phase 3 design is testing doses up to 6 milligrams over 48 weeks — an earlier readout showed a 19.2 percent mean weight reduction at the highest dose, compared to 1.4 percent on placebo (SEC S-1 Filing). An oral formulation also cleared Phase 2, producing a 12.1 percent mean weight reduction at 26 weeks (SEC S-1 Filing).
Kailera enters an obesity drug market that Eli Lilly and Novo Nordisk have effectively partitioned between them, even as both face continued manufacturing constraints and pricing pressure from Medicare negotiations. Pfizer is also circling through its Metsera acquisition. Whether ribupatide can actually compete on efficacy, safety, and price will depend entirely on what the Phase 3 data shows — and that data is still months away.
The comparison to tirzepatide's SURMOUNT-1 results is suggestive, not definitive. Phase 2 trials are not Phase 3 trials. Patient populations, endpoints, and statistical designs differ. A Phase 3 failure to replicate the weight-loss signal would be lethal to the investment thesis. So would a discovery that the drug's safety profile diverges meaningfully from its competitors'. And Kailera has never brought a drug to market — it has no approved product, no revenue, and a Chinese manufacturing partner whose supply chain reliability carries real geopolitical risk in the current regulatory environment.
The IPO is real. The science is early. The pitch is compelling enough to watch.
